Idenix Pharmaceuticals Inc., which we refer to together with our wholly owned subsidiaries as Idenix, we, us or our, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, our primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV. HCV is a leading cause of liver disease. The World Health Organization estimates that approximately 150 million people worldwide are chronically infected with HCV and an additional three to four million people are infected each year. Currently, only a portion of people infected with HCV are diagnosed and we believe it will take many years to screen and diagnose these patients. The current standard of care for genotype 1 HCV-infected patients includes pegylated interferon and ribavirin, or Peg-IFN/RBV, as part of the treatment regimen. Peg-IFN/RBV is poorly tolerated by patients and, as a result, patients refuse to initiate treatment or discontinue therapy due to intolerability. We believe there are large market opportunities in the U.S. and outside the U.S. to treat patients with any genotype with an all-oral regimen. Our strategic goal is to develop safe, potent and convenient all-oral combinations of direct-acting antiviral, or DAA, drug candidates that are pan-genotypic without the use of Peg-IFN/RBV. Our objective is to develop once-daily agents that have low potential for drug-drug interaction, high tolerability and are designed for use in multiple combination regimens. We are seeking to build a combination development strategy, both internally and with partners, to advance the future of HCV treatments.
![Idenix Pharmaceuticals logo](https://files.capedge.com/424B5/0001193125-12-326223/g386975g52w50.jpg)
Company profile
Ticker
IDIX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Novirio Pharmaceuticals LTD
SEC CIK
Corporate docs
IRS number
450478605
Latest filings (excl ownership)
15-12G
Securities registration termination
15 Aug 14
SC TO-T/A
Third party tender offer statement (amended)
6 Aug 14
25-NSE
Exchange delisting
5 Aug 14
8-K
Completion of Acquisition or Disposition of Assets
5 Aug 14
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 14
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 14
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 14
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 14
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 14
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 14
Latest ownership filings
SC 13D/A
Idenix Pharmaceuticals Inc
12 Aug 14
SC 13D/A
Idenix Pharmaceuticals Inc
12 Aug 14
SC 13D/A
Idenix Pharmaceuticals Inc
29 Jul 14
SC 13D
Idenix Pharmaceuticals Inc
13 Jun 14
SC 13D/A
Idenix Pharmaceuticals Inc
3 Apr 14
SC 13D/A
Idenix Pharmaceuticals Inc
14 Feb 14
SC 13G/A
Idenix Pharmaceuticals Inc
12 Feb 14
SC 13G/A
Idenix Pharmaceuticals Inc
11 Feb 14
SC 13G/A
Idenix Pharmaceuticals Inc
7 Feb 14
SC 13D/A
Idenix Pharmaceuticals Inc
4 Feb 14